



## ASX ANNOUNCEMENT

22 March 2007

### **First HVAD<sup>TM</sup> Patient Reaches 12 Months**

HeartWare is pleased to announce that the first patient implanted with the HVAD<sup>TM</sup> Left Ventricular Assist Device has today been supported on the HVAD<sup>TM</sup> for 12 months.

On 22 March 2006, Mr Georgi Petkov became the first patient ever to be implanted with the HVAD<sup>TM</sup>. The implant was conducted at the Vienna General Hospital by Dr George Wieselthaler, Clinical Director of Mechanical Circulatory Support at the University of Vienna. Mr Petkov, who was 48 years old at the time, was suffering end-stage heart failure and was on the heart transplant waiting list.

Following the procedure, Dr Wieselthaler commented that “the patient’s early post-operative recovery has been excellent.” Over the ensuing year, Mr Petkov has continued to make an extraordinary recovery. Today he leads a normal and active life. A professional opera singer prior to the onset of heart failure, Mr Petkov has even returned to the stage and performs benefit concerts in Vienna.

Dr Wieselthaler, who has since implanted a further three HVAD<sup>TM</sup> pumps, commented:

*“It is extremely gratifying to witness the dramatic improvement in Mr Petkov’s quality of life over the past 12 months. The HVAD<sup>TM</sup> implant procedure is quick and easy, which expedited Mr Petkov’s hospital discharge and rehabilitation from NYHA Class IV to Class I. My other HeartWare patients have experienced similar clinical outcomes. All continue to be supported by their pumps and are home spending quality time with their loved ones. I am very impressed with the performance and reliability of the HeartWare HVAD<sup>TM</sup> System.”*

To date, nine patients have been implanted with the HeartWare HVAD<sup>TM</sup>, including four at Vienna General Hospital, three at Royal Perth Hospital and two at Hannover Medical Centre. On a cumulative basis, these patients have been supported for a total of over 1,300 days. All patients continue to recover well and none have yet received a heart transplant. The first two patients have successfully passed the 180-day primary endpoint of the study.



## About HeartWare

HeartWare is developing a family of proprietary circulatory assist devices to treat patients with heart failure. HeartWare's lead device, the HVAD™, is currently progressing through an international clinical trial. With a volume of 45cc, the HVAD™ is the smallest "3rd generation" pump and the only full output device implantable routinely within the thoracic cavity.

HeartWare's miniaturization platform enables the development of smaller devices, potentially implantable by minimally invasive surgical techniques. Pre-clinical studies are underway for HeartWare's MVAD™, a pump one third the size of the HVAD™. HeartWare's IV-VAD™, a pump one tenth the size of the HVAD™, is at early prototype stage.

For further information:

[www.heartware.com.au](http://www.heartware.com.au)

Howard Leibman

Director Corporate Development

HeartWare Limited

+61 2 8215 7604 / 0402 440644

Media enquiries:

Stuart Barton

Gavin Anderson & Company

+61 2 9552 4499 / 0404 054 857